<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5860">
  <stage>Registered</stage>
  <submitdate>8/03/2016</submitdate>
  <approvaldate>8/03/2016</approvaldate>
  <nctid>NCT02756858</nctid>
  <trial_identification>
    <studytitle>An Extension Study of ANAVEX2-73 in Patients With Mild to Moderate Alzheimer's Disease</studytitle>
    <scientifictitle>An Extension Study of ANAVEX2-73 in Patients With Mild to Moderate Alzheimer's Disease</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>ANAVEX2-73-003</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Alzheimer's Disease</healthcondition>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Alzheimer's disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Dementias</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - ANAVEX2-73

Experimental: ANAVEX2-73 Oral as assigned in ANAVEX2-73-002 - 


Treatment: drugs: ANAVEX2-73


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</outcome>
      <timepoint>Up to 104</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Mini-mental state examination score (MMSE)</outcome>
      <timepoint>Baseline; Weeks: 13, 26, 39, 52, 65, 78, 91, &amp; 104</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Score from ADCS-ADL (Alzheimer's Disease Co-operative Study - Activities of Daily Living Inventory)</outcome>
      <timepoint>Baseline; Weeks: 13, 26, 39, 52, 65, 78, 91, &amp; 104</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Hamilton Psychiatric Rating Scale for Depression (HAM-D) Score</outcome>
      <timepoint>Baseline; Weeks: 13, 26, 39, 52, 65, 78, 91, &amp; 104</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Previous exposure to ANAVEX2-73 via participation in Phase 2a Study of ANAVEX2-73
             Adaptive-Trial-Design With Repeated Doses, MTD Finding, Pharmacodynamic and
             Bioavailability Evaluation in Patients With Mild to Moderate Alzheimer's Disease With
             a 12-Month Open Label Follow-Up Period (ANAVEX2-73-002)</inclusivecriteria>
    <inclusiveminage>55</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>85</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Have not previously participated Phase 2a Study of ANAVEX2-73 Adaptive-Trial-Design
             With Repeated Doses, MTD Finding, Pharmacodynamic and Bioavailability Evaluation in
             Patients With Mild to Moderate Alzheimer's Disease With a 12-Month Open Label
             Follow-Up Period (ANAVEX2-73-002)</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/03/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>32</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/11/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Melbourne Health - The Royal Melbourne Hospital - Melbourne</hospital>
    <hospital>Austin Health - Heidelberg Repatriation Hospital - Melbourne</hospital>
    <hospital>Caulfield Hospital - Melbourne</hospital>
    <hospital>Nucleus Network- Centre for Clinical Studies - Melbourne</hospital>
    <hospital>St. Vincent's Hospital - Melbourne</hospital>
    <postcode>3050 - Melbourne</postcode>
    <postcode>3084 - Melbourne</postcode>
    <postcode>3162 - Melbourne</postcode>
    <postcode> - Melbourne</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Anavex Life Sciences Corp.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This open label extension study is designed to provide continued access to ANAVEX 2-73 for
      eligible subjects with mild to moderate Alzheimer's Disease who have previously participated
      in the Anavex sponsored study ANAVEX2-73-002.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02756858</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>